chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was given the Moderna COVID-19 vaccine. About 15 minutes into her wait time her tongue started to feel numb and her neck was itching. We gave Benadryl and recommended going to an Urgent Care. She didn't want to go when we suggested and wanted to wait to see if the Benadryl would help. We kept here for another 30 minutes to watch her to make sure it didn't progress.  Went to check on her again and she stated that she was feeling better. We told her that if it got any worse to go the the ER or an Urgent care and she agreed that she would.
High fever 102.1F to 103.3F, vomiting, coughing, nasal congestion, irritability and shaking.
No adeverse affects reported; patient "received her 3rd dose of GARDASIL 9 sooner than what was indicated." Nurse Prescriber stated that second dose was administered on 9/4/2019 and 3rd dose was received on 9/18/2019.; This spontaneous report was received from a nurse prescriber via a company representative referring to a 15 years old female patient. The patient's concurrent condition included migraine. Her medical history included migraine prior to injection. Concomitant medication and drug reactions/allergies were not reported.  On 04-SEP-2019, the patient was vaccinated with the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (lot number reported as R032747) (expiration date and route of administration were unknown; strength and dose not reported) in left deltoid for prophylaxis. On 18-SEP-2019, the patient was vaccinated with the third dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) (lot number reported as 1621931) (expiration date and route of administration were unknown; strength and dose not reported) for prophylaxis (inappropriate schedule of product administration). The patient's mother told the medical assistant that the patient was here for flu vaccination and the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) vaccination. The medical assistant administered the second dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) to the patient-error caught immediately. The patient's mother was advised of error. No other injections were administered. The mother was advised to inform as soon as possible if any adverse effects occurred. The medical assistant then was educated after the incident-must look and verify injection due date prior to administration. The patient nor her family sometime was clear what was needed. No adverse effects were reported.
This case was reported by a other health professional via sales rep and described the occurrence of chills in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a day after receiving SHINGRIX, the patient experienced chills, fever and nausea. On an unknown date, the outcome of the chills, fever and nausea were unknown. It was unknown if the reporter considered the chills, fever and nausea to be related to SHINGRIX. Additional details were provided as follows: This case was received from an office manager. The age at vaccination was not reported. The patient had no pain at injection however that evening presented with fever, chills and nausea. The reporter agreed to follow up.
11/6 urticaria, induration, erythema. Benadryl 25mg po q4. 11/7 resolved.
Eye pain; sore throat; diarrhea; bone pain; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number: unknown) via an unspecified route of administration on 06Apr2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. It was unknown whether the patient received any other vaccine in 4 weeks and unknown whether the patient had COVID prior to vaccination. On 06Apr2021, the patient experienced eye pain, sore throat, diarrhea and bone pain. The patient did not tested for COVID since vaccination. The patient did not receive treatment for the events. The outcome of the events was recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Initial information received from other company (Pfizer) on 13 August 2013. The information was initially received from a consumer. Manufacturer report number: US-PFIZER INC-2012272135. A female patient whose at the time of event, medical history and concomitant medications were not reported, had received a dose of Tetanus Toxoid vaccine from unknown manufacturer (batch number, dose number, route and anatomical site of administration were not reported) on an unspecified date. On an unspecified date after receiving Tetanus Toxoid vaccine, the patient developed allergy (not specified). Corrective treatments and laboratory investigations were not reported. The outcome of event was not reported. Documents held by sender: none. Follow-up information received on 27 November 2013: As the current reporter has no further information. End of follow-up.
Chest/back/abdomen scattered maculopapular erythematous lesions x 50. Illness considered to be generalized vaccinia. Tx w/Zyrtec upon initial visit to MD. Upon follow-up exam, lesions were resolving well. Cause unknown - cannot relate specifically to vax.
low grade temp for a couple hours Fatigue for two days Mild to severe headache for two and a half days
No additional AE; An HBP is calling in to report an AE for a patient that was given an expired dose of VAQTA. Because the HBP also had questions regarding the potency of the dose and possible need for re-vaccination this agent requested to speak with an HCP. A nurse t; This spontaneous report was received from a  health professional referring to a patient of unknown age and gender. Information regarding the patient medical history, concomitant medications, drug allergies or reactions was not provided.       On 04-OCT-2022, the patient was vaccinated with hepatitis a vaccine, inactivated (VAQTA) 0.5 milligram, intramuscular for prophylaxis, lot number U004366 has been verified to be valid for hepatitis a vaccine, inactivated expired date 01-OCT-2022 (expired product administered). No additional adverse events were reported. The health care business professional was inquiring about the potency of the dose.
24OCT96 reported to school nurse pt hosp steas edema & cyanosis lt arm;mom did not feel secondary to vax;30OCT96 ?neuro complication lt hand affecting several fingers;
Woke up to extreme nerve discomfort, had trouble walking downstairs.  Was considering need to go to ER but took advil which eventually relieved pain/discomfort enough to go back to sleep.  Next day wa; Woke up to extreme nerve discomfort; Booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 25-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 29Apr2022 as dose 4 (booster), single (Lot number: FM9992) at the age of 25 years for covid-19 immunisation. The patient's relevant medical history included: "Type1 Diabetes" (unspecified if ongoing). Concomitant medication(s) included: INSULIN; VYVANSE. Past drug history included: Known allergies: lorabid, reaction(s): "Known allergies: lorabid". Vaccination history included: BNT162b2 (Dose Number: 3, Batch/Lot No: FF2593), administration date: 01Nov2021, when the patient was 24-year-old, for Covid-19 Immunization; BNT162b2 (Dose Number: 2, Batch/Lot No: EP6955), administration date: 21Apr2021, when the patient was 24-year-old, for Covid-19 Immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EP6955), administration date: 22Mar2021, when the patient was 23-year-old, for Covid-19 immunization. The following information was reported: IMMUNISATION (non-serious) with onset 29Apr2022, outcome "unknown", described as "Booster"; NEURALGIA (non-serious) with onset 29Apr2022 at 01:00, outcome "recovered" (01May2022), described as "Woke up to extreme nerve discomfort"; GAIT DISTURBANCE (non-serious) with onset 29Apr2022 at 01:00, outcome "recovered" (01May2022), described as "Woke up to extreme nerve discomfort, had trouble walking downstairs.  Was considering need to go to ER but took advil which eventually relieved pain/discomfort enough to go back to sleep.  Next day was". Therapeutic measures were taken as a result of gait disturbance, neuralgia.  Additional Information: The patient was treated with Advil, the patient did not had covid prior to vaccination and was not tested for covid post vaccination. The patient did not receive any other vaccine with four weeks.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200650000 similar report from same reporter
Vertigo-  Pretty intense on the 2nd of March.  Somewhat less after that but still persistent at this time.
This case was reported by a physician, via a sales representative, and described the occurrence of Guillain-Barre in a patient who received EPZICOM tablet for human immunodeficiency virus and INFLUENZA. Concurrent medical conditions included human immunodeficiency virus. Co-suspect medication included INFLUENZA. Concurrent medications included REYATAZ and NORVIR. On an unknown date, the patient started Abacavir sulfate & lamivudine (oral) at 1 capsule daily. In 2012, the patient received a dose of INFLUENZA (intramuscular injection). In 2012, approximately 1 month after receiving the INFLUENZA, the patient experienced Guillain-Barre. This case was assessed as medically serious by GSK. Treatment with Abacavir sulfate & lamivudine was discontinued. At the time of reporting, the outcome of the event was unknown. The reporting physician considered the event was possibly related to treatment with INFLUENZA and unlikely related to the treatment with Abacavir sulfate & lamivudine. The physician stated the patient was a long established user of Abacavir sulfate & lamivudine. The physician thought that the Guillain-Barre diagnosis may have been a result of the patient receiving the flu shot approximately one month prior, but the patient was sent to the neurologist and discontinued EPZICOM and REYATAZ.
Visual disturbances; Dizziness; This spontaneous case, initially received from other health professional (pharmacist) on 28-Sep-2018, concerns a male patient of an unspecified age.  On 27-Sep-2018, the patient was administered Afluria Quadrivalent (influenza vaccine, dose: 0.5 ml, route of administration: intramuscular, anatomical location: left deltoid, batch number: YF40408 and expiry date: 30-Jun-2019) for protection against seasonal influenza.  On 28-Sep-2018, one day after vaccination, the patient began to experience visual disturbance and dizziness. The patient had two episodes of it on the day of this report. It was reported that, the patient did not receive any treatment for the events.   At the time of this report the outcome of the events were unknown.  The reporter assessed the case as non-serious.; Reporter's Comments: A male patient of an unspecified age experienced visual disturbance and dizziness one day after the administration of Afluria Quadrivalent. The company assessed the causality as related due to plausible temporal relationship between the events and suspect vaccine.
FLUZONE HIGH-DOSE was administered to a patient and some of the vaccine did leak out where the needle connects to the syringe with no adverse event; Initial information regarding this unsolicited non-valid non-serious case via agency (reference number: 00317908) was received from pharmacist and transmitted to Sanofi 15-Oct-2020.  This case involved a patient who was administered with INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] and some of the vaccine did leak out where the needle connects to the syringe (Syringe issue).  Relevant medical history, past medical treatment, vaccination details and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot UJ512AA, expiry date: 30-Jun-2021) via unknown route in unknown administration site for prophylactic vaccination and some of the vaccine did leak out where the needle connects to the syringe (syringe issue).  Pharmacist said it may be a faulty needle or something.   No adverse event was reported at the time of reporting.  Relevant laboratory test was not reported.  Final diagnosis was Not Applicable fluzone high-dose was administered to a patient and some of the vaccine did leak out where the needle connects to the syringe with no adverse event.
high pitched screaming 4 hrs; swollen leg; fever (100-102); swollen red eyelids-briefly;
Pt received HBV ## and IPV #2 on 8/16/05. Rash started late afternoon 8/17/05. Erythematous macular rash over exposed body parts (arms, legs, face) body and diaper area spared. Appears to be Gianotti-Crosti syndrome.
This case was reported by a consumer via other manufacturer and described the occurrence of influenza-like symptoms in a 58-year-old male patient who received SHINGRIX. Co-suspect products included Flu Seasonal QIV Dresden. On 20th February 2018, the patient received SHINGRIX (intramuscular). On an unknown date, the patient received Influenza vaccine at an unknown dose. On 19th February 2018, less than a year after receiving Influenza vaccine, the patient experienced runny nose. On 20th February 2018, the patient experienced influenza-like symptoms. The patient was treated with Aspirin and TYLENOL. On 20th February 2018, the outcome of the runny nose was recovered/resolved. On an unknown date, the outcome of the influenza-like symptoms was not recovered/not resolved. It was unknown if the reporter considered the influenza-like symptoms and runny nose to be related to SHINGRIX and Influenza vaccine. Additional details were provided as follows: This case was reported by an employee (other manufacturer), who himself was the patient. The patient mentioned that in his family there is a syndrome of inflammatory autoimmune disorders and manifest of flu like so there was remote possibility that the two are related or completely unrelated autoimmune disorders and manifest of flu like so there was remote possibility that the two are related or completely unrelated. The patient had received Influenza vaccine last fall in September or October 2017. The patient had a clinic in their local plant they were offering free SHINGRIX vaccines so the patient signed up and went there to receive the vaccine. The patient confirmed that vaccine was not prescribed by any doctor hence doctor details were not probed over call. The patient specified SHINGRIX was onetime injection which was to be followed in 2 months by a booster. A day before SHINGRIX vaccination, the patient had a runny nose briefly but he did not take anything out for it because it did not persist and the next morning when he went to get the SHINGRIX vaccine he felt fine. He did not take much medical treatment for runny nose because like it he said it resolved by itself and was not major and it could had been attributed to allergies (general statement) or through changes in temperature or anything, he did not associate but possibly coming down the flu at the same time but he mentioned it now because he supposed it was a possibility. There was no reason to blame the vaccine for the symptoms but the patient was just fulfilling the reporting applications. The patient had flu like symptoms late night on the vaccination day of SHINGRIX. The patient had taken Aspirin (650 mg, tablet orally once) and TYLENOL (1000 mg, capsule orally once) by himself as treatment but no other medications. The patient had not done any lab work. The patient did not have any product details including the batch number or expiry details and dose of the SHINGRIX vaccine. The patient did not have the phone number because he did not have my work computer at home. This case was not associated with product complaint, and medical information request.
Immediate itching at injection site which lasted about 3 minutes. Following that I felt slightly dizzy and anxious. about 20 minutes after injection I developed mild chest pain and mild chest tightness and a slight cough. 2 hours after injection, continued chest pain and worsening cough. I took a Zyrtec and albuterol and my symptoms resolved at 1430, 3.5 Hours after injection.
8 y/o female received first dose of COVID Pfizer vaccine in the left deltoid at 11.50am.  After patient completed the 15 minute observation, patient left building with grandmother.  Patient fell outside of building and told grandmother that her "right side of body went numb".  Vitals at 12:07 were 112/82 blood pressure, 22 respiration, 83 strong/regular pulse and 100% SpO2.  Neuro vitals intact, grip strength intact bilaterally.  Had patient sit for 10 minutes, states "feeling better".  Very active, playing with stickers and crayons.  Released @ 1222 without complaint.
Patient received a expired vaccine 16Apr2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received a expired vaccine 16Apr2022) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007J21-2a) for COVID-19 vaccination.     History relating to mentioned adverse event and  both Acute and Chronic illnesses at the time of  vaccination was reported as no. Other vaccines given within 1 month prior to  Moderna COVID-19 vaccine was reported as no.  Concurrent medical conditions included COPD, Asthma and Drug allergy (Tylonol).    On 22-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received a expired vaccine 16Apr2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received a expired vaccine 16Apr2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. On 22 Apr 2022, the patient received the first booster dose of the vaccine. Treatment information was not provided.
Moderna vaccine given 11:15.  Ten minutes later she experienced facial itching, cough and shortness of breath, expiratory wheezing.   Self administered Benadryl 25mg PO x1, Epi-pen auto injector (right thigh).  O2 by nasal cannula.   Evaluated by physician and EMS transported patient to Emergency Room at 11:40
Swelling of at injection site, up to shoulder to base of neck and down to elbow. Skin was red, hot and blistery. Patient had severe, intense pain and limitation from swelling.
2/9/21 plt ct 33 (baseline 78), 2/10/21 plt ct 46, 2/11/21 plt ct 6 then 3, admitted to hospital, given high dose steroids and IVIG, symptoms now improving, but experiencing ongoing thrombocytopenia
Information has been received from a Physician's Assistant concerning a 3 year old female who in 1998 was vaccinated with Varicella Virus live. In May 2000, the patient developed herpes zoster of the eye and was hospitalized. Additional information has been requested
SHORTNESS OF BREATH THAT COMES AND GOES; This spontaneous report received from a patient concerned a 61 year old male.  The patient's height, and weight were not reported. The patient's concurrent conditions included: blindness. The patient had no known drug allergies.  The patient received covid-19 vaccine (Janssen dose series 1) (suspension for injection, route of admin not reported, batch number: 206A21A, expiry: 21-SEP-2021) dose was not reported, 1 total, administered on 03-MAY-2021 in left arm for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, he started having Shortness of Breath that comes and goes (dose series 1). The patient did not have any symptoms until about 3 weeks or a month ago from the time of reporting on 05-NOV-2021. He would have Shortness of Breath for couple of hours in the afternoon and it went away. The patient stated he was having Shortness of Breath at the time of reporting. He called to inquire on how long would this last for and if it would go away. He did not have any other symptoms. He had not consulted with a doctor.  On 02-NOV-2021, the patient received the Moderna Booster and he reported having the Shortness of Breath that comes and goes (dose series 1) before getting the Moderna Shot (Non-company dose series 2).   The action taken with covid-19 vaccine was not applicable.  The patient had not recovered from shortness of breath that comes and goes.  This report was non-serious.
As the pharmacy worker was giving me the shot I felt a rushing sound almost like rushing blood going through my left ear, and since then my hearing hasn?t been the same. There is a ringing sound and I can?t seem to hear very well out of that ear. It often feels like when you?re in an airplane and the airplane is descending.  My ears constantly feel like they need to be popped.
I went online and saw this one lady that had this weird feeling too; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (I went online and saw this one lady that had this weird feeling too) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013A21A and 026B21A) for COVID-19 vaccination.     The patient's past medical history included Raynaud's syndrome, Psoriasis (psoriasis in the mouth.), Alopecia, Groin infection and Candida NOS (candida or lichen planus in my mouth.).   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (I went online and saw this one lady that had this weird feeling too).        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
4 spots on stomach & back; nausea & vomiting; t105; very lethargic; 4FEB94 dx chickenpox;
Headache with the first COVID-19 Vaccine; A little bit of chest pain; Heart Troubles; This is a spontaneous report from a contactable consumer. This 56-year-old female consumer reported that she the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EJ1685) at single dose for vaccination on 22Dec2020. Relevant medical history included Rheumatoid, Asthma, Artery disease, Gastroparesis.  Relevant concomitant drugs were unknown. The patient had a headache with the first COVID-19 Vaccine and a little bit of chest pain. Stated she has heart troubles. Outcome of events was unknown.
I have tinnitus in both ears since about 1-1/2 weeks after my first dose of the Pfizer vaccine which I received on 3/5/2021.
Patient received first COVID vaccine Pfizer on 4/14/21. Subsequently, he developed fever, dry cough, HA, chills/shakes, nausea with diarrhea. Patient presented to ED on 4/29/21 and found to be COVID-19 ( ) w/hypoxemia. File this incident for record keeping.
About a month after vaccine i tested positive for covid. Few days before testing positive i woke up feeling as if i was getting a bad cold. as the days continued i started to feel worse. Congestion body ache and lethargy. I was prescribe prednisone and i was talking Allegra, Tylenol, and cough medicine.
Pain behind sternum and pain on inhalation 4 days after receiving flu vaccine. Went to hospital and had multiple test done. 6 different pills daily plus a blood thinner while in hospital. Hospital results are waiting on transcription.
Fever to 102.5 for 4 hrs. Treated with MOTRIN.